Terazosin Capsule
Product Images NDC 71335-3123

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71335-3123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

A dual chart figure from Study 1 showing the mean change in total symptom score and mean increase in peak flow rate (mL/sec) from baseline over a 3-month period. The left graph compares Terazosin and placebo in symptom score changes, while the right graph compares peak flow rate increases between Terazosin and placebo groups.*

FDA Label Image

Image Description (Figure 02)

A line graph titled "Mean Change in Total Symptom Score from Baseline" for a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months from 0 to 30, and the y-axis shows mean change from baseline ranging from 0 to -7. The graph depicts a steep decline in symptom scores during the first three months, followed by a gradual stabilization below -4 for the remaining period. Data points include markers with error bars and asterisks indicating statistical significance.*

FDA Label Image

Image Description (Figure 03)

A line chart titled 'Mean Change in Peak Flow Rate from Baseline' showing data from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents time in months (0 to 30), and the y-axis shows mean change from baseline in mL/sec (0 to 4.5). Data points with error bars are plotted over time, with several marked by asterisks indicating statistical significance.*

FDA Label Image

Label (Lbl713353123)

Label for Terazosin Capsules, USP, 10 mg strength, oral dosage form. The label indicates a package size of 30 capsules. It shows the NDC 71335-3123-1 and identifies Bryant Ranch Prepack as the repackager and OrBion Pharmaceuticals Private Ltd. as the manufacturer. Storage and handling instructions to protect from light and moisture and to store at controlled room temperature are included.*

FDA Label Image

Image Description (Structure001)

Chemical structure of Terazosin showing its molecular arrangement including aromatic rings, nitrogen atoms, oxygen-containing groups, and associated hydrochloride and water molecules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.